help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chabner, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chabner, B. A.
The Oncologist, Vol. 7, Suppl 3, 34-41, August 2002
© 2002 AlphaMed Press

Cytotoxic Agents in the Era of Molecular Targets and Genomics

Bruce A. Chabner

Massachusetts General Hospital, Boston, Massachusetts, USA

Correspondence: Bruce Chabner, M.D., Hematology/Oncology Associates, 100 Blossom Street, Cox 640, Boston, Massachusetts 02114-2617, USA. Telephone: 617-724-3200; Fax: 617-724-3166; e-mail: bchabner{at}partners.org

Cancer treatment is evolving due to the development of molecularly targeted agents and the utilization of pharmacogenomics and pharmacogenetics to identify patients who are at an increased risk for toxicity or may be uniquely responsive to cytotoxic therapies. By identifying polymorphisms in the human genome that confer changes in the ability to metabolize or activate cancer agents, a more patient-specific treatment approach can be initiated. Molecularly targeted therapies such as PS-341, flavopiridol, Iressa, and anti-vascular endothelial growth factor antibodies may help to overcome resistance to cytotoxic therapies by lowering the apoptotic threshold and increasing cytotoxicity. Using molecularly targeted agents in combination with traditional cytotoxic agents may increase the percentage of patients who achieve disease stabilization and prolonged survival. With the development of genetic tools and genotyping of tumor and patient prior to initiating treatment, antitumor efficacy may be increased with a substantial reduction in toxicity.

Key Words. Pharmacogenomics • Pharmacogenetics • Polymorphism • Molecular targeting




This article has been cited by other articles:


Home page
 CA Cancer J ClinHome page
G. Y. Yang, T. D. Wagner, M. Fuss, and C. R. Thomas Jr.
Multimodality Approaches for Pancreatic Cancer
CA Cancer J Clin, November 1, 2005; 55(6): 352 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. B. Brunner, K. A. Cengel, S. M. Hahn, J. Wu, D. L. Fraker, W. G. McKenna, and E. J. Bernhard
Pancreatic Cancer Cell Radiation Survival and Prenyltransferase Inhibition: The Role of K-Ras
Cancer Res., September 15, 2005; 65(18): 8433 - 8441.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y. J. Chua and D. Cunningham
Adjuvant Treatment for Resectable Pancreatic Cancer
J. Clin. Oncol., July 10, 2005; 23(20): 4532 - 4537.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. G. Roberts Jr, T. J. Lynch Jr, and B. A. Chabner
The Phase III Trial in the Era of Targeted Therapy: Unraveling the "Go or No Go" Decision
J. Clin. Oncol., October 1, 2003; 21(19): 3683 - 3695.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
E. P. Tamm, P. M. Silverman, C. Charnsangavej, and D. B. Evans
Diagnosis, Staging, and Surveillance of Pancreatic Cancer
Am. J. Roentgenol., May 1, 2003; 180(5): 1311 - 1323.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2002 by AlphaMed Press.